RCT: Abiraterone and Olaparib for metastatic castration-resistant prostate cancer.
9 Jun, 2022 | 10:21h | UTCAbiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer – NEJM Evidence
Commentary on Twitter
Combination treatment with abiraterone and olaparib increased progression-free survival regardless of homologous recombination repair gene mutation status in patients with metastatic castration-resistant #ProstateCancer treated in the first-line setting. https://t.co/CAUDF2ZErG pic.twitter.com/YARZa8AUXJ
— NEJM Evidence (@NEJMEvidence) June 3, 2022